Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $2.14 in the prior trading day, Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $1.99, down -7.24%. In other words, the price has decreased by -$7.24 from its previous closing price. On the day, 3.51 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ALLO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.35 and its Current Ratio is at 9.35. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.18.
On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 18 ’25 when MESSEMER DEBORAH M. sold 13,313 shares for $2.43 per share. The transaction valued at 32,351 led to the insider holds 144,316 shares of the business.
MESSEMER DEBORAH M. bought 13,313 shares of ALLO for $32,329 on Feb 18 ’25. On Feb 03 ’25, another insider, Douglas Earl Martin, who serves as the SVP, General Counsel of the company, sold 6,404 shares for $1.71 each. As a result, the insider received 10,951 and left with 587,848 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 10405.02 while its Price-to-Book (P/B) ratio in mrq is 0.90.
Stock Price History:
Over the past 52 weeks, ALLO has reached a high of $5.78, while it has fallen to a 52-week low of $1.32. The 50-Day Moving Average of the stock is 1.39%, while the 200-Day Moving Average is calculated to be -18.93%.
Shares Statistics:
A total of 209.50M shares are outstanding, with a floating share count of 134.74M. Insiders hold about 35.74% of the company’s shares, while institutions hold 65.95% stake in the company.
Earnings Estimates
Allogene Therapeutics Inc (ALLO) is presently subject to a detailed evaluation by 10.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.32, with high estimates of -$0.25 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$1.17 and -$1.38 for the fiscal current year, implying an average EPS of -$1.31. EPS for the following year is -$1.33, with 11.0 analysts recommending between -$1.02 and -$1.59.
